Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 10, 2001, Pages 2733-2739

  Barditch Crovo, P ^a   Deeks, S G ^a   Collier, A ^a   Safrin, S ^a   Coakley, D F ^a   Miller, M ^a   Kearney, B P ^a   Coleman, R L ^a   Lamy, P D ^a   Kahn, J O ^a   McGowan, I ^a   Lietman, P S ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FUNCTION; LIVER TOXICITY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS REPLICATION;

ADENINE; ADULT; ANTI-HIV AGENTS; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; RNA, VIRAL;

EID: 0034806946     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.10.2733-2739.2001     Document Type: Article

References (14)

1. Synthesis, in vitro biological evaluation and oral bioavailability of prodrugs of the antiretroviral agent 9-[2-(phosphonomethoxy)-propyl]adenine (PMA)
2. The safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy) propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults
3. The safety and efficacy of adefovir dipivoxil, a novel anti-HIV therapy, in HIV infected adults
4. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capacity in vitro
5. Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: In vitro analyses
6. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl) adenine (PMPA), bis(isopropyloxymethylcarbonyl) PMPA
7. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)-propyl]adenine (PMPA) in dogs
8. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl) PMPA against various drug-resistant human immunodeficiency virus strains
9. mne infection depends critically on timing of initiation and duration of treatment
10. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine
11. Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques
12. 9-[2-Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques
13. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA